Merck announced on Nov. 7, 2020 that it is entering into a collaboration with Transcenta, a biotherapeutics company, to initiate continuous manufacturing for protein therapeutics.

According to a Transcenta press release, the companies will start off by developing and designing process technologies, single-use systems, and automation, with plans to eventually focus on an expanding process and digital technologies to optimize a continuous manufacturing process. The companies will also co-develop a single-use flow-through polishing system using Transcenta’s integrated continuous bioprocessing (ICB) Platform as part of the partnership.

View Full Article→